...
首页> 外文期刊>Radiology >Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!).
【24h】

Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!).

机译:通过分子生物学将放射肿瘤学和影像学联系起来(或者现在治疗和诊断已经分开了,是时候再次聚在一起!)。

获取原文
获取原文并翻译 | 示例
           

摘要

Among the areas defined by the National Cancer Institute as "Extraordinary Opportunities for Research Investment" that are highly relevant to the technology-oriented disciplines within the broad field of radiology are cancer imaging, defining the signatures (ie, underlying molecular features) of cancer cells, and molecular targets of prevention and treatment. In molecular target credentialing, a specific molecular target is imaged, the molecular signature is defined, a treatment is given, and the effect of the intervention on the image findings and the signature is then evaluated. Such an approach is used to validate the proposed target as a legitimate one for cancer therapy or prevention and to provide the opportunity to ultimately individualize therapy on the basis of both the initial characteristics of the tumor and the tumor's response to an intervention. Therapeutic radiation is focused biology (ie, radiation produces molecular events in the irradiated tissue). Radiation can (a) kill cancer cells by itself, (b) be combined with cytotoxic or cytostatic drugs, and (c) serve to initiate radiation-inducible molecular targets that are amenable to treatment with drugs and/or biologic therapies. Focused biology can be anatomically confined with various types of external beams and with brachytherapy, and it can be used systemically with targeted radioisotopes. These new paradigms link diagnostic imaging, radiation therapy, and nuclear medicine in unique ways by way of basic biology. It is timely to develop new collaborative research, training, and education agendas by building on one another's expertise and adopting new fields of microtechnology, nanotechnology, and mathematical analysis and optimization.
机译:与放射学广泛领域中以技术为导向的学科高度相关的,被美国国家癌症研究所定义为“研究投资的巨大机会”的领域是癌症成像,它定义了癌细胞的特征(即潜在的分子特征) ,以及预防和治疗的分子靶标。在分子靶标认证中,对特定分子靶标成像,定义分子标记,进行处理,然后评估干预对图像发现和标记的影响。这种方法被用来验证所提议的目标是用于癌症治疗或预防的合法目标,并提供机会根据肿瘤的初始特征和肿瘤对干预的反应来最终个体化治疗。治疗性放射是聚焦生物学(即,放射在被辐照的组织中产生分子事件)。辐射可以(a)自身杀死癌细胞,(b)与细胞毒性或细胞抑制药物联合使用,并且(c)用于启动适合于药物和/或生物疗法治疗的辐射诱导性分子靶标。聚焦生物学可以在解剖学上受限于各种类型的外部束和近距离放射疗法,并且可以与靶向放射性同位素一起全身使用。这些新的范例通过基础生物学以独特的方式将诊断成像,放射治疗和核医学联系在一起。通过彼此的专业知识并采用微技术,纳米技术以及数学分析和优化的新领域,及时制定新的协作研究,培训和教育议程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号